{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:25:23Z","timestamp":1781922323929,"version":"3.54.5"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Prior to the 2020 release of a joint consensus guideline on monitoring of vancomycin therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections, clinicians had escalated vancomycin doses for 2 decades while targeting trough concentrations of 15 to 20 \u00b5g\/mL, leading to an increased frequency of nephrotoxicity. For MRSA infections, the 2020 guideline recommends adjusting doses to achieve a 24-hour area under the concentration-time curve (AUC) of 400 to 600 \u00b5g\u2009\u00b7\u2009h\/mL; however, monitoring of trough concentrations has been entrenched for 3 decades. Calculating dose regimens based on AUC will require obtaining an increased number of vancomycin serum concentrations and, possibly, advanced software. The aim of this investigation was to determine the relationship between AUC and trough concentration and the influence of dosing regimen on goal achievement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The relationship between trough concentration and AUC was explored through derivation of an equation based on a 1-compartment model and simulations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>24-hour AUC is related to dosing interval divided by half-life in a nonlinear fashion. The target trough concentration can be individualized to achieve a desired AUC range, and limiting use of large doses (&amp;gt;15-20 mg\/kg) can protect against excessive 24-hour AUC with trough-only monitoring.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After initially determining pharmacokinetic parameters, subsequent monitoring of AUC can be accomplished using trough concentrations only. Trough concentration may be used as a surrogate for AUC, although the acceptable target trough concentration will vary depending on dosing interval and elimination rate constant. This work included development of an AUC-trough equation to establish a patient-specific target for steady-state trough concentration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab457","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:45:07Z","timestamp":1638344707000},"page":"534-539","source":"Crossref","is-referenced-by-count":12,"title":["The relationship of vancomycin 24-hour AUC and trough concentration"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-465X","authenticated-orcid":false,"given":"David E","family":"Nix","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice & Science and Department of Medicine, University of Arizona, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice & Science, University of Arizona, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R","family":"Matthias","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice & Science, University of Arizona, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"2022032109050509200_CIT0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022032109050509200_CIT0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022032109050509200_CIT0003","first-page":"835","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022032109050509200_CIT0004","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration- time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022032109050509200_CIT0005","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022032109050509200_CIT0006","first-page":"487","article-title":"The importance of dosing interval in limiting vancomycin AUC with trough monitoring","volume":"77","author":"Nix","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"key":"2022032109050509200_CIT0007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01086153","article-title":"Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients","volume":"4","author":"Sawchuk","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"key":"2022032109050509200_CIT0008","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1310\/hpj4409-751","article-title":"Optimizing vancomycin doseing through pharmacodynamic assessment targeting area under the concentration-time curve\/minimum inhibitory concentration","volume":"44","author":"Deryke","year":"2009","journal-title":"Hosp Pharm"},{"key":"2022032109050509200_CIT0009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.25.4.433","article-title":"Pharmacokinetics of vancomycin in patients with various degrees of renal function","volume":"25","author":"Matzke","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"2022032109050509200_CIT0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3476(80)80347-7","article-title":"Clinical pharmacology and efficacy of vancomycin in pediatric patients","volume":"96","author":"Schaad","year":"1980","journal-title":"J Pediatr"},{"key":"2022032109050509200_CIT0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","article-title":"Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight","volume":"16","author":"Ducharme","year":"1994","journal-title":"Ther Drug Monit"},{"key":"2022032109050509200_CIT0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0897190017743133","article-title":"Evaluation of intravenous vancomycin pharmacokinetic parameters in patients with acute brain injury","volume":"32","author":"Oswalt","year":"2019","journal-title":"J Pharm Pract"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab457\/42499027\/zxab457.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/7\/534\/42953241\/zxab457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/7\/534\/42953241\/zxab457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T09:05:45Z","timestamp":1647853545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/7\/534\/6444799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,11,27]]},"published-print":{"date-parts":[[2022,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab457","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,11,27]]}}}